Cell apoptosis and proliferation in obstructive uropathy.
Distinct patterns of cell proliferation and apoptosis have been recognized for tubular, interstitial, and glomerular cells in chronic obstructive uropathy (OU). In many experimental models of OU, tubular cell apoptosis develops quickly after ureter ligation, peaks between 7 and 24 days postobtruction (about 30-fold of control), and tapers thereafter. Apoptosis initially involves the dilated collecting ducts, but subsequently spreads to other tubules. Tubular cell apoptosis probably accounts for renal tissue loss in OU because a direct correlation between its degree and the decline in dry kidney weight is well-documented. Pronounced tubular cell proliferation occurs shortly after ureter ligation, peaks at about day 6 (60-fold above control), and quickly subsides to baseline. Because the peak of tubular cell proliferation immediately precedes the onset of tubular cell apoptosis, a pathogenetic link may exist between these two processes. Interstitial cell apoptosis occurs with an increasing frequency throughout the course of OU (up to 35-fold above control). Interstitial cell proliferation appears in a bimodal pattern with the early peak coinciding with that of tubular cell proliferation and consisting mostly of fibroblasts, whereas the later peak consists mostly of inflammatory cells. Glomerular cell apoptosis and proliferation are not different from control, which explains, in part, the structural integrity of the glomeruli throughout the disease course. Although the general pathways of cell apoptosis and proliferation are well known, the molecular control of these processes in OU is poorly understood. In addition, whether apoptosis or proliferation of tubular and interstitial cells is differentially regulated remains to be studied. However, several molecules known to be activated or overexpressed in kidney with OU may modulate cell apoptosis and proliferation. The relevant functions of these molecules include induction of apoptosis (angiotensin II, reactive oxygen species, jun-N-terminal kinase, p53), inhibition of the cell cycle (transforming growth factor-beta, p21), inhibition of apoptosis (clusterin, epidermal growth factor, insulin-like growth factor, bcl-2, osteopontin), or promotion of interstitial fibroblast proliferation (platelet-derived growth factor).
Truong
L D
LD
Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX 77030, USA.
Sheikh-Hamad
D
D
Chakraborty
S
S
Suki
W N
WN
D000804:Angiotensin II / Q000502:physiology; D000818:Animals; D017209:Apoptosis; D002455:Cell Division; D051152:Clusterin; D016158:Genes, p53 / Q000502:physiology; D006023:Glycoproteins / Q000502:physiology; D006801:Humans; D007684:Kidney Tubules / Q000473:pathology*; D018832:Molecular Chaperones; D010982:Platelet-Derived Growth Factor / Q000502:physiology; D017382:Reactive Oxygen Species; D016212:Transforming Growth Factor beta / Q000502:physiology; D014517:Ureteral Obstruction / Q000473:pathology*
C495242:CLU protein, human; D051152:Clusterin; D006023:Glycoproteins; D018832:Molecular Chaperones; D010982:Platelet-Derived Growth Factor; D017382:Reactive Oxygen Species; D016212:Transforming Growth Factor beta; D000804:Angiotensin II